• Aethlon Medical's Hemopurifier has received ethics approval in India for a clinical trial targeting solid tumors resistant to anti-PD-1 therapies.
• The trial will assess the safety, feasibility, and optimal dosage of Hemopurifier in patients with stable or progressive disease.
• Hemopurifier aims to improve therapeutic response by removing tumor-produced extracellular vesicles from the bloodstream.
• Aethlon anticipates beginning patient recruitment in Q4 2024, with the trial informing future oncology efficacy studies.